Shire Biologics (SHPGY) Continues Adidas Cap Tumblr
Auxilium Pharmaceuticals Completes $43 Million Private FinancingXOMA (XOMA) Exercises Option To Defer $40 Million; Convertible Loan Payment To Genentech (DNA)
has developed a unique method for supplying blood to the coronary vessels for the treatment of coronary artery disease ("CAD"). An estimated 298,000 patients in the US alone and 557,000 worldwide will undergo coronary artery bypass graft ("CABG") in 2004. Additionally 1,085,000 patients will undergo percutaneous transluminal coronary angioplasty ("PTCA"). The Company's VSTENT(TM) Myocardial Implant will target both groups of patients where there is currently no equivalent product available. The company has raised $55 million to fund research, development, and clinical trials of its VCAB(TM)/VSTENT(TM) device. Nancy Briefs, Percardia's President CEO, and her senior management team have over a century of combined experience developing and commercializing devices for cardiovascular medicine.
a second close on its Series D Financing. In total, the Company raised $23.5 Million in their Series D financing round. Investors in this round include, Percardia LLC, Prism Venture Partners, Atlas Venture, Advance Technology Ventures, Medtronic, Crescendo Ventures, and Vanguard Ventures. The Company also announced it has acquired the HeartStent intellectual property portfolio which includes 28 issued US patents as well as numerous patent applications in the field of ventricular sourcing.
NitroMed, Inc. Announces Its Initial Public OfferingSmith Nephew At High On Bid Talk, Analysts Wary
5 /PRNewswire/ , a venture funded medical device company focused on the development of new therapeutic solutions for the treatment of coronary artery disease, announced today that it recently completed Adidas Hat Cap
The Development Of Its Vaccine Business: Investment For Expansion Of Vaccine Facility In Quebec City And Construction Of Vaccine Research Centre In Laval; Investing CAN $46.5 Million; 100 New JobsNeuroMed Technologies Inc. Raises US$32 Million In Series C Round Led By MPM Capital
Pharmion Corporation Announces Initial Public Offering Of Common StockDefending Esperion
1 Announces Close Of 23 5 Million Of Series D Financing And Purchase Of HeartStent Intellectual Property
(1) VSTENT(TM) Myocardial Implant is a trademark of CONTACT: Christopher P. Joyce of , +1 603 882 1803,Ext. 223Related News
A clinical evaluation of the VSTENT(TM) Myocardial Implant(1) is currently taking place in Europe as part of the ADVANTAGE [Adjunctive Treatment with the VCAB(TM)/VSTENT(TM) Myocardial Implant System in Coronary Artery Bypass Graft (CABG) Patients] Study. Similar to traditional intra coronary stents that are used to hold open blocked arteries, the VSTENT(TM) Myocardial Implant provides in situ scaffolding that establishes a direct channel to deliver oxygenated blood from the left ventricle of the heart to a targeted coronary vessel. The first generation implant is a balloon deployable stainless steel stent, which consists of biomaterials that have a proven safety record of implantation into humans. The VSTENT(TM) Myocardial Implant is a Class III cardiovascular implant requiring Pre Market Approval (PMA) in the United States and the CE Mark in the European Union (EU).
Percardia Vice President CFO, Christopher P. Joyce, commented "We are extremely pleased to have continued strong support from all of our investors, each of which participated in Adidas Cap New Arrival this Series D financing round. In addition we are fortunate Jordan Caps Black
to have secured the HeartStent patent portfolio which solidifies our intellectual property position in the field of ventricular sourcing."
States Flock To Biotech Like Gamblers To Lottery TicketsRoche Keen On Genentech Type Acquisitions
Hermes Belt Details
Cincinnati Reds Caps
New Era Minnesota Twins
Chicago Bears Cap
Gucci Belt With Flowers
Adidas Cap Winter
Ferragamo Belts Blue
Gucci Belt For Womens
Nike Cap Womens Tumblr
Adidas Hat Womens Black
Gucci Belt Snake White
Nike Hats Visors
Nike Cap Mens
Nike Hats Without Top
New Era Washington Nationals